---
title: "Optimizing Basal Insulin Therapy for Type 2 Diabetes: The Role of Once-Weekly Insulins"
id: "endocrine-news-0-advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins/"
published_at: "2026-11-01T17:35:48.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Optimizing Basal Insulin Therapy for Type 2 Diabetes: The Role of Once-Weekly Insulins
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins/)
- **Published At:** 2026-11-01T17:35:48.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Basal insulin is often necessary for individuals with type 2 diabetes (T2D) as the disease progresses. - Insulin therapy should be timely and individualized, considering patient symptoms and comorbidities. - The 2026 ADA Standards recommend starting insulin when A1C exceeds 10% or glucose is ≥300 mg/dL. - Once-weekly basal insulins, like insulin icodec and efsitora alfa, reduce injection frequency and maintain glycemic control. - Clinical trials show that these insulins match the efficacy of daily doses while lowering treatment burden. - Practitioners should account for patient preferences, potential hypoglycemia risks, and individual formulation differences when prescribing.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/october-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in-the-era-of-once-weekly-insulins/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Advancing Basal Insulin Therapy in Type 2 Diabetes: Individualizing Treatment in the Era of Once-Weekly Insulins November 1, 2026 Print this article Share this article ##### Despite major advances in cardiometabolic therapies, many people with type 2 diabetes (T2D) will eventually require basal insulin. The clinical challenge is not only initiating insulin in appropriate patients but also optimizing therapy while avoiding overbasalization and minimizing treatment burden. Once-weekly basal insulins represent an important advancement that may help simplify insulin therapy for appropriate patients. SPONSORED CONTENT BY NOVO NORDISK ## The Modern Treatment Algorithm for Type 2 Diabetes In caring for adults with type 2 diabetes (T2D), conversations about insulin often happen later than they should. For many patients, adding insulin can feel like a sign of personal failure, while clinicians may view initiation as a complex step that is easier to postpone. However, neither perspective reflects the underlying biology. T2D is progressive, and over time pancreatic beta-cell function declines, making insulin a necessary part of care for many patients. For example, UKPDS 49 highlighted that only about one-quarter of participants maintained an A1C below 7% with monotherapy at 9 years after diagnosis, illustrating that treatment must evolve as the disease advances. [1,2] The modern T2D treatment algorithm has moved beyond focusing on glucose lowering alone. For patients with established or high risk for atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, obesity, or other metabolic comorbidities, treatment selection now prioritizes therapies with demonstrated cardiorenal, weight, and metabolic benefits. Current guidance also prefers GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist therapy before insulin for most adults who do not have severe hyperglycemia or hyperglycemic crisis. [1] While addressing cardiovascular, renal, and weight-related comorbidities should be prioritized, achieving and maintaining glycemic targets may require insulin replacement. Basal insulin remains foundational because it works to dampen hepatic glucose release during the night and between meals.[1] The clinical task is to introduce it at the right time, titrate it toward a defined fasting glucose objective, and recognize when it has accomplished what basal insulin can reasonably accomplish. ## When Basal Insulin Is the Appropriate Next Step Basal insulin should be considered when individualized glycemic goals are unlikely to be reached with current pharmacotherapy, despite attention to adherence, access, lifestyle, and appropriate use of noninsulin therapies. The decision is particularly urgent when a patient has symptomatic hyperglycemia, catabolic features such as unintentional weight loss or ketosis, or very high blood glucose levels. Under the 2026 ADA Standards, these features — symptomatic hyperglycemia, an A1C above 10%, or glucose at or above 300 mg/dL — warrant starting insulin even when a patient is already on other agents and irrespective of how long they have had diabetes.[1] For patients without severe hyperglycemia, insulin initiation is individualized. Even with appropriate cardiometabolic therapies, such as metformin, GLP-1 receptor agonist, dual GIP/GLP-1 receptor agonist, or an SGLT2 inhibitor, some patients remain above target as endogenous insulin secretion declines. In this setting, adding basal insulin is not a retreat from modern therapy; it is a complementary response to progressive beta-cell dysfunction. When insulin is used, current guidance supports retaining agents with cardiovascular, kidney, weight, or metabolic benefit when tolerated and clinically appropriate, while reassessing medications that increase hypoglycemia risk or add little incremental value.[1] In practice, reluctance to start insulin often reflects a combination of patient and clinician concerns. Some patients may fear hypoglycemia, weight gain, or the complexity of an insulin regimen. Clinicians may anticipate training demands, follow-up needs, or titration uncertainty. A more productive conversation frames insulin as a tool rather than a verdict. It should include the purpose of basal insulin, the individualized fasting glucose target, the monitoring plan, recognition and treatment of hypoglycemia, and a clear schedule for reassessment. Shared decision-making also means discussing the practical differences among available basal options, including injection frequency, device characteristics, dose-conversion requirements, cost, coverage, and the patient’s confidence in following the regimen. | **Clinical vignette** A 58-year-old adult with T2D is taking metformin, a GLP-1 receptor agonist, and an SGLT2 inhibitor. A1C remains 9.1%, and fasting glucose values are usually 175 to 215 mg/dL despite confirmed medication access and use. There are no catabolic symptoms, but the current regimen is unlikely to achieve the individualized goal without insulin replacement. Rather than waiting for further deterioration, the clinician introduces basal insulin with a defined fasting target, a monitoring and titration plan, and follow-up that is frequent enough to address concerns early. The existing agents are reviewed for continued cardiorenal and weight benefit rather than reflexively discontinued. | | --- | ## Once-Weekly Insulins as an Emerging Therapeutic Class Basal insulin delivery has evolved from formulations with pronounced peaks and variable duration to long-acting and ultra-long-acting analogs that provide more predictable glucose lowering effects. Once-weekly basal insulins extend that evolution by distributing basal insulin activity across a 7-day dosing interval. For a person who would otherwise require one basal insulin injection every day, a once weekly basal insulin would decrease the number of scheduled basal injections from approximately 365 to 52 per year. This difference may matter for some adults with T2D, particularly those who prefer fewer injections. However, it should not necessarily be assumed that less frequent dosing will directly improve adherence, treatment satisfaction, or glycemic outcomes for every patient. Missing a weekly dose has different implications from missing a daily dose, and the prolonged duration of action heightens the importance of accurate dose calculation, medication reconciliation, titration, glucose monitoring, and patient education. Multiple phase 3 clinical trials have evaluated once‑weekly basal insulins in adults with T2D, including both insulin‑naive adults and those previously treated with basal insulin. Across these studies, once-weekly basal insulin regimens generally achieved A1C reductions that were noninferior to once-daily basal insulin comparators, with small A1C or time-in-range differences favoring weekly therapy in some analyses; however, results varied by formulation, study population, and trial design. A class-level systematic review and meta-analysis of 14 randomized controlled trials involving 8,487 adults with T2D found a small mean A1C difference favoring weekly therapy, a modest improvement in time in range, and no statistically significant difference in level 2 or 3 hypoglycemia. However, since these pooled estimates reflect data across different products, they should not be interpreted as evidence of the efficacy or safety of any individual formulation. Additionally, because trial level results differed, and each once‑weekly insulin has distinct pharmacokinetics, dosing, and clinical evidence, findings should not be assumed to apply uniformly across the class.[6-8,11,12,19] Selected early-phase and clinical pharmacology studies have also explored higher-risk circumstances such as prolonged fasting, exercise, and inadvertent excess dosing. In one study of 54 adults with T2D, hypoglycemia was evaluated during prolonged fasting, fasting combined with exercise, and double dosing of the once-weekly basal insulin efsitora alfa. Most events were level 1 hypoglycemia, level 2 hypoglycemia was infrequent, and no severe hypoglycemic episodes were observed.[13] In a separate study of 30 physically active adults with T2D, time below range remained low during a standardized exercise challenge and an 18-hour fast while at steady state with insulin icodec, with no clinically significant or severe hypoglycemia reported, although some participants required protocol-directed glucose rescue.[20] Another randomized crossover study evaluating double or triple doses of once-weekly insulin icodec in adults with T2D found low rates of clinically significant hypoglycemia, no severe hypoglycemic events, and physiological responses to hypoglycemia were similar to those observed with double and triple doses of insulin glargine U100.[21] In summary, once-weekly basal insulins may reduce injection burden while providing glycemic efficacy comparable to once-daily basal insulin in appropriately selected adults with T2D. Treatment selection should be individualized according to hypoglycemia risk, cognitive and functional status, the reliability of medication-taking routines, the ability to recognize and respond to glucose excursions, concurrent therapies, access, and patient preference. Individual formulations within the class differ in pharmacokinetics, dose-conversion methods, concentration, delivery device, titration algorithm, clinical evidence, and safety profile. Evidence, dosing instructions, and risk-management strategies should not be assumed to transfer from one formulation to another. | **U.S. regulatory status as of September 2026** Insulin icodec-abae was approved by the FDA on March 26, 2026, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is a U-700 insulin administered once weekly. Dosing, switching, missed-dose instructions, warnings, and precautions are product-specific; clinicians should consult the current Prescribing Information.[14] Insulin efsitora alfa-gobe was approved by the FDA on September 24, 2026, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available as U-500 and U-1000 formulations administered once weekly. Dosing, switching, missed-dose instructions, warnings, and precautions are product-specific; clinicians should consult the current Prescribing Information.[22] | | --- | ## Clinical Considerations with Once-Weekly Basal Insulins | **Changes in physical activity** Exercise can increase glucose utilization during and after activity. Counsel patients to review expected activity changes, monitor glucose more closely when risk is elevated, carry rapid-acting carbohydrate, and recognize delayed hypoglycemia. Published analyses of once-weekly insulin studies have not shown a consistent additional physical activity-attributed hypoglycemia signal compared with daily basal insulin, but these data do not remove the need for individualized precautions. [13,15,20] | | --- | | **Planned fasting, procedures, or surgery** Plan in advance. Document the exact insulin product, concentration, weekly dose, date and time of the last dose, and the next scheduled dose. Coordinate outpatient and procedural teams, consider CGM and point-of-care glucose needs, review other glucose-lowering therapies – including SGLT2 inhibitors – and establish a hypoglycemia and hyperglycemia response plan. Because weekly basal insulin remains active across several days, clinicians should use product-specific guidance rather than applying a generic “hold the basal dose” rule. In the small prospective study described above, CGM-detected time below 54 mg/dL was low at 0.2% ± 0.8% of the 18-hour fast, and no clinically significant or severe hypoglycemic episodes were reported. However, intravenous glucose was administered to 15 of 30 participants under the study protocol when plasma glucose fell below the prespecified threshold of 72 mg/dL. These results reinforce the importance of close monitoring and a predefined rescue plan; they do not establish that prolonged fasting or peri-procedural NPO status is risk-free. [20] | | --- | | **Acute illness or disrupted nutrition** Illness may increase or decrease insulin requirements and can change hydration, oral intake, and ketone risk. Increase glucose monitoring as clinically appropriate, assess hydration and ketones when indicated, and give patients clear thresholds for contacting the care team. Do not improvise short-term changes to a weekly basal dose without considering the product’s
## Related Clinical Research

- [Safiglipron vs dapagliflozin in type 2 diabetes: phase 3 randomized double-blind OUTSTAND-2 results](https://medichelpline.com/clinical-feed/nature-0-oral-small-molecule-glp-1ra-safiglipron-versus-dapagliflozin-in-type-2-diabetes.md)
- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Safiglipron: once-daily oral GLP-1 receptor agonist shows significant HbA1c reductions in early ty](https://medichelpline.com/clinical-feed/nature-1-oral-small-molecule-glp-1-receptor-agonist-safiglipron-in-early-type-2-diabetes.md)
- [SGLT2 inhibitors vs GLP-1 RAs and osteoarthritis risk in type 2 diabetes: a multi-institutional co](https://medichelpline.com/clinical-feed/plos-one-16-comparative-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-on.md)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.